CTL Medical to acquire Amedica's spine business for up to $10M: 4 things to know

Shayna Korol -   Print  |

Amedica will sell its commercial spine business to CTL Medical for up to $10 million.

Here are four things to know:

1. CTL Medical will become the exclusive owner of Amedica's metal and silicon nitride spine portfolio, with access to future silicon nitride spine technologies.

2. All intellectual property related to the core silicon nitride biomaterial technology will remain with Amedica, which will serve as CTL's exclusive original equipment manufacturer silicon nitride product provider.

Amedica's board chairman Sonny Bal, MD, said, "Divesting the sales organization will drive down costs, while allowing Amedica to focus on additional OEM revenue opportunities outside of spine, such as in the dental and arthroplasty markets."

3. The transaction is expected to close in the third quarter of 2018.

4. Following the transaction, CTL Medical will change its name to CTL Amedica.

More articles on devices:
NuVasive expands spine portfolio with new TLIF device: 5 insights
Stryker, Medtronic, SpineFrontier & more: 8 device company notes
140 spine devices received FDA 510(k) clearance in 2018 so far


© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers